» Articles » PMID: 25634179

Impact of Coexisting Pulmonary Diseases on Survival of Patients with Lung Adenocarcinoma: a STROBE-compliant Article

Overview
Specialty General Medicine
Date 2015 Jan 31
PMID 25634179
Citations 12
Authors
Affiliations
Soon will be listed here.
Abstract

Asthma, chronic obstructive pulmonary disease (COPD), and pulmonary tuberculosis (TB) are common pulmonary diseases associated with lung cancer. Besides, smoking is more prevalent in Taiwanese men. This study evaluated gender disparities in coexisting pulmonary diseases on survival of patients with lung adenocarcinoma. Patients newly diagnosed with lung cancer between 2003 and 2008 were identified from Taiwan National Health Insurance Research Database. Cases with lung adenocarcinoma were further confirmed using the Cancer Registry Database and followed up until the end of 2010. Cox proportional hazard regression was used to calculate the hazard ratio (HR) of coexisting asthma, COPD, and/or TB to estimate all-cause mortality risk. During the study period, 13,399 cases of lung adenocarcinoma were identified. The HRs of adenocarcinoma in men and women were 1.20 (95% confidence interval [CI], 1.10-1.30) and 1.05 (95% CI, 0.95-1.16), respectively, for individuals with asthma, 1.32 (95% CI, 1.16-1.51) and 0.97 (95% CI, 0.89-1.05), respectively, for COPD, and 0.99 (95% CI, 0.93-1.06) and 1.06 (95% CI, 0.86-1.32), respectively, for individuals with TB. Specifically, among men with coexisting pulmonary diseases, the HRs were 1.63 (95% CI, 1.25-2.13), 1.31 (95% CI, 1.08-1.59), and 1.23 (95% CI, 1.11-1.36) for individuals with asthma + COPD + TB, asthma + COPD, and COPD + TB, respectively. However, there was no increase risk of mortality among women with coexisting pulmonary diseases. Coexisting pulmonary diseases are at an elevated risk of mortality among male patients with lung adenocarcinoma. Such patients deserve greater attention while undergoing cancer treatment.

Citing Articles

The diagnosis interval influences risk factors of mortality in patients with co-existent active tuberculosis and lung cancer: a retrospective study.

Xiong M, Xie S, Wang Y, Cai C, Sha W, Cui H BMC Pulm Med. 2023; 23(1):382.

PMID: 37817103 PMC: 10563245. DOI: 10.1186/s12890-023-02674-3.


Clinical characteristics and survival of patients concurrently diagnosed with lung cancer and active pulmonary tuberculosis.

Lee H, Kang H, Kang J, Kim J, Lee S, Kim S Transl Cancer Res. 2022; 11(8):2671-2680.

PMID: 36093537 PMC: 9459664. DOI: 10.21037/tcr-22-272.


Comparison of clinical and imaging features between pulmonary tuberculosis complicated with lung cancer and simple pulmonary tuberculosis: a systematic review and meta-analysis.

Sun W, Zhang L, Liang J, Li X, Yang Y, Sun W Epidemiol Infect. 2022; 150:e43.

PMID: 35105410 PMC: 8895721. DOI: 10.1017/S0950268822000176.


Impact of coexistent preserved ratio impaired spirometry on the survival of patients with lung cancer: Analysis of data from the Korean Association for Lung Cancer Registry.

Heo I, Kim H, Lee S, Yoo J, Ju S, Jeong Y Thorac Cancer. 2021; 12(18):2478-2486.

PMID: 34337879 PMC: 8447913. DOI: 10.1111/1759-7714.14095.


Pulmonary function is implicated in the prognosis of metastatic non-small cell lung cancer but not in extended disease small cell lung cancer.

Lee S, Choi Y, Seo J, Yong Lee S, Kim J, Joo Kang E J Thorac Dis. 2020; 11(11):4562-4572.

PMID: 31903245 PMC: 6940228. DOI: 10.21037/jtd.2019.10.77.


References
1.
Papaiwannou A, Zarogoulidis P, Porpodis K, Spyratos D, Kioumis I, Pitsiou G . Asthma-chronic obstructive pulmonary disease overlap syndrome (ACOS): current literature review. J Thorac Dis. 2014; 6 Suppl 1:S146-51. PMC: 3966158. DOI: 10.3978/j.issn.2072-1439.2014.03.04. View

2.
Iachina M, Green A, Jakobsen E . The direct and indirect impact of comorbidity on the survival of patients with non-small cell lung cancer: a combination of survival, staging and resection models with missing measurements in covariates. BMJ Open. 2014; 4(2):e003846. PMC: 3927932. DOI: 10.1136/bmjopen-2013-003846. View

3.
Tammemagi C, Neslund-Dudas C, Simoff M, Kvale P . Smoking and lung cancer survival: the role of comorbidity and treatment. Chest. 2004; 125(1):27-37. DOI: 10.1378/chest.125.1.27. View

4.
Inghammar M, Ekbom A, Engstrom G, Ljungberg B, Romanus V, Lofdahl C . COPD and the risk of tuberculosis--a population-based cohort study. PLoS One. 2010; 5(4):e10138. PMC: 2854124. DOI: 10.1371/journal.pone.0010138. View

5.
Caramori G, Casolari P, Cavallesco G, Giuffre S, Adcock I, Papi A . Mechanisms involved in lung cancer development in COPD. Int J Biochem Cell Biol. 2010; 43(7):1030-44. DOI: 10.1016/j.biocel.2010.08.022. View